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Abstract 
The impact assessment of repeated mass ivermectin treatment on onchocerciasis in Abia state, south eastern 
Nigeria was carried out between June and September 2011, using skin snipping method. Abia state is made up of 
17 Local Government Areas, eight of which are endemic for onchocerciasis (2 hyper-endemic and 6 meso-
endemic LGAs). The study captured the two LGAs of the state that were rated as hyper-endemic by REMO 
assessment and had been receiving treatment since 1995. Out of 547 individuals skin snipped, only 3 (0.55%) 
were infected with microfilariae of Onchocerca volvulus, and this occurred in one community Amiyi-Obilohia. 
The distribution of infection showed that 0.50% of the infected were males while 0.58% were females. The 
overall age specific prevalence showed that infection only occurred in individuals 60 years and above, who were 
low compliers and were not treated during the last treatment period. A CMFL of 0.28 mf/mg obtained is an 
indication that ivermectin is an effective microfilaricide. 
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1. Introduction 
Ivermectin, a microfilaricide, developed by Merck & Co. Inc. and launched commercially in 1981 remains 
currently the most effective broad-spectrum antiparasitic agent against a wide range of nematode and arthropod 
parasites of plants, animals and human (Campbell, et al., 1983; Ottesen and Campbell, 1994). Ivermectin has 
been extensively used in veterinary medicine for treating internal and external parasites (Campbell, 1985) and 
was later introduced for human Onchocerciasis (WHO, 1987). It is considered one of milestones of tropical 
disease treatment and a revolutionary breakthrough, as it has an effective microfilaricidal action that could clear 
effective microfilariae from the skin with minimal side effect (Aziz et al., 1982; Campbell, 1991). The advent of 
ivermectin has revolutionized the treatment of onchocerciasis, ivermectin being the first effective drug safe 
enough for mass chemotherapy (Chijioke, 2009). Ivermectin has been shown to be an effective long-lasting 
microfilaricide which has no serious adverse effect and suitable for mass treatment (Ali, 2006).  
 
One of the most important and striking characteristics of ivermectin is that despite its short half-life, a single 
dose not only eliminates skin microfilariae but also provides long lasting suppression of microfilariderma ( 
Awadzi et al.,1986). Ivermectin kills 99% of microfilariae with a single treatment (APOC/WHO, 2005). 
Repeated treatments cause mass reduction in the number of multicellular embryonic stages of the worm (Duke et 
al., 1991). Multiple ivermectin treatments at various intervals result in increased numbers of calcified nodules 
and of dead or moribund female and male adult worms. There are reduced numbers of male worms per nodule 
and reduced insemination of female worms (Duke et al., 1992).  
A pioneering study by Aziz et al (1982), demonstrated the extraordinary potent effect of ivermectin in causing a 
dramatic reduction in skin snip microfilarial counts within 48 hours of oral doses of 30-ug/kg and 50-ug/kg. 
Subsequent studies have confirmed and expanded these findings (Awadzi et al., 1986; Diallo et al., 1986).  
Ivermectin is more effective at 100 to 200-ug/kg than 50-ug/kg, and cause a massive reduction in skin 
microfilarial counts which reached a minimum at about 2 weeks after dosing (Chijioke, 2009). Studies in 
Senegal and Mali showed that after 15 to 17 years of treatment, the prevalence of infection and the intensity of 
transmission fell below postulated threshold values for elimination (APOC /WHO, 2010).Treatment was stopped 
and a follow-up data over a period of three years showed no evidence of new infection or transmission. This 
provided the first evidence that ivermectin treatment can eliminate onchocerciasis infection and transmission. 
In Nigeria, ivermectin has drastically reduced the incidence of onchocerciasis. A study conducted in the Imo 
River Basin revealed that community microfilarial load (CMFL) as well as the community nodule rate were 
reduced from 57.3 mf/ss and 59% respectively to 18.3 mf/ss and 21% within the first 4 years of ivermectin 
treatment (Dozie et al., 2004a). Furthermore, reports of nodule dissolution (Ukaga et al., 2001, Emukah et al., 
2004), improvement in eye lesions/low vision (Emukah et al., 2004) and onchocercal skin disease (Dozie et al., 
2004b), expulsion of intestinal worms (Abanobi et al., 1994) and resumption of menstruation (Anosike and 
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Abanobi, 1995) are documented. The present study is designed to assess the impact of ivermectin on 
onchocerciasis in Abia state, Nigeria, where ivermectin has been offered annually for over 14 years.  
 
 
2. Materials and Methods 
2.1. Study Area: Abia state located in south eastern Nigeria, lies between latitude 4o 451 and 6o 151 North and 
longitude 6o 301 and 8o 91 East. It is bordered on the North and Northeast by Ebonyi and Enugu states 
respectively and on the east by cross River and Akwa Ibom states. Its southern border is shared with River State 
while its western border is shared with Imo and Anambra States. 
 Ivermectin MDA programmes for onchocerciasis were deemed necessary in the state based on the result from 
the national onchocerciasis assessment surveys (Rapid Epidemiology Mapping of Onchocerciasis) that showed 
meso-endemic/hyper-endemic prevalence of the forest stain of onchocerciasis (estimated nodule rates >20% in 
adults) throughout much of the south eastern Nigeria (Emukah et al., 2004). Ivermectin distribution started in the 
state in 1991 with Mbala-Isuochi chosen as pilot area. By 1994/1995, the control spread to other LGAs of the 
state (Onuoha, 2004).These LGAs are currently the CDTI sites in the state. Currently, the project has completed 
fourteen years in 2011 and has 564 communities at risk of the disease (WHO/APOC, 2009). 
 
2.2.  Research Ethics: Ethical review and clearance of the research protocol, research instruments and informed 
consent procedures were obtained from the Ethical Review Committee of the Department of Animal and 
Environmental Biology, Imo State University, Owerri. Permission was sought from the State Ministry of Health 
and community leaders. Community meetings were held in all sampled communities to explain the research 
objectives and procedures, and the right of individuals to decide whether to participate in the examination or not. 
Before each examination, each individual who voluntarily came to the examination point and agree to participate 
signed or put a thumb print if not literate, on the examination form to indicate consent. For children, one of the 
parents or a responsible guardian signed the examination form. All subjects who voluntarily presented 
themselves at the screening center for the survey were asked for identification data (name, age, sex, occupation 
and number of years resident).  
 
2.3. Sample Collection Process: The samples were collected from the two hyper-endemic LGAs of Abia State 
(Umunneochi and Isuikwuato LGAs). The sample population was determined according to Krejcie and Morgan 
(1970) and samples collected from eight communities selected by a stratified simple random sampling (4 
communities from each LGA).  After obtaining individuals verbal consent, participants were examined for 
microfilariae in the skin, subcutaneous nodules and leopard skin, and had their visual acuity tested. The 
examinations were conducted as follows: 
• Microfilariae in skin: Parasitological examination was carried out by two techniques namely 
skin snipping and microscopy (Ukaga and Nwoke, 2007) on 547 individuals. Prior to the skin 
snipping, the area of the skin (left and right iliac crest) were carefully swabbed with cotton 
wool soaked in 70% alcohol and allowed to dry. A sterilized needle on a syringe was pushed 
into the skin where two bloodless skin snips were taken. A sterile scalpel was used for cutting. 
No two individuals used the same needle or scalpel to prevent transmission of blood viruses. 
The skin biopsies were placed in microtitre plates containing 3 drops of 40% normal saline and 
incubated for 24 hours at room temperature. The emerging microfilariae from each anatomical 
site were observed directly on the microtitre plates using inverted microscope and recorded in 
the individual clinical and parasitological form. The preservation of any specimen that could 
not be examined after 24 hours was carried out by the addition of 10% formalin into each 
microtitre well.  
• Palpation for the Presence of Mobile Nodules:  Participants were examined in a private area 
for characteristic subcutaneous onchocercal nodules by partially disrobing and then undergoing 
palpation around the lower ribs, back, waist, iliac crest, sacrum, lips and legs (Albiez et al., 
1988). The locations of the nodules were noted on the individual’s patient record form. 
• Physical Examination of Skin for Papular Dermatitis and Leopard skin: While examining 
for the mobile nodules, popular dermatitis and leopard skin were also sought around the lower 
ribs, back, waist, iliac crest, sacrum and hips, as well as on the head, legs and arms. Acute and 
chronic popular dermatitis could not be distinguished (Murdoch et al., 2002). Notations of 
locations of popular dermatitis and leopard skin when found were made on the anatomic 
diagram in the individual patient record.  
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• Visual Acuity Screening: The participants stood at a measured distance of six meters from 
the examiner and were asked to tell how many fingers were shown to them by the examiner 
alternating between one, two or three fingers ( Emukah et al., 2004). The patients were 
allowed to use both eyes. Visual impairment was considered as three failures to properly 
identify the correct number of fingers shown by the examiner. 
 
2.4. Statistical Analysis: The data obtained from skin snipping were analyzed using Epi-info version 6 
soft ware [CDC, Atlanta]. Percentages were used to determine the different levels of prevalence while 
the chi-square (X2) test was used to determine the level of significance of the onchocercal symptoms 
among the community members.  
 
3.0.  Results 
A total of 547 individuals were examined for the microfilariae of Onchocercal volvulus. Only 3 (0.55%) were 
infected. All infected individuals came from one community-Amiyi-Obilohia. The infected individuals were low 
compliers who had not taken the drug for more than three times since the treated started in 1995 and were not 
treated during the last treatment period (Table 1). The result also revealed that 1(0.50%) of the infected were 
males while 2(0.58%) were females (Table 1). The overall sex-specific prevalence showed that out of 62 
individuals skin snipped from Amiyi-Obilohia (the only community where infection was observed) only 
3(4.84%) of the total population sampled were infected. The gender prevalence in that community showed that 
1(6.26%) of the infected were males while 2(4.35%) were females (Table 2).  The overall aged-specific 
prevalence of infection in the sampled communities revealed that infection only occurred in individuals 60 years 
and above (Table 3). A moderate skin microfilarial count of 55 was obtained with community microfilarial load 
(CMFL) of 0.28mf/mg (Table 4). 
Table 5 showed the onchocercal symptoms observed during the period of investigation. Out of 547 individuals 
examined, 142 (26.0%) showed symptoms: 50 (9.1%) had mobile nodules, 49 (9.0%) had ocular infections, 24 
(4.4%) had itching, 18 (3.3%) had leopard skin and 1(0.2%) had lizard skin. The communities most infected with 
symptoms were Amakpoke with infection rate of 44.3%, followed by Amiyi-Obilohia with infection rate of 
41.9%. The least infected community was Obiagu-Uturu with infection rate of 1.1%. Since the calculated X2 cal = 
50.56 > the critical value X2tab = 49.8%, we conclude that at 0.05 level of significance, the identified symptoms 
among community members are significantly different.  
 
Table 1: Overall Prevalence of infected individuals with Onchocerciasis in the sampled Communities. 
Community  
Number 
Examined 
Number and Percentage 
infected 
Number and  percentage 
uninfected 
Umuobiala 63 0 63 (100) 
Amiyi Obilohia 62 3(4.84) 59 (95.16) 
Obiagu-Uturu 36 0 36 (100) 
Amiyiuhu 98 0 98 (100) 
Mbala-Isuochi 104 0 104 (100) 
Amuda-Isuochi 42 0 42 (100) 
Amakpoke 70 0 70 (100) 
Lokpanta 72 0 72 (100) 
Total 547 3(0.55) 544 (99.45)  
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Table 2: Overall sex-specific prevalence of Onchocerciasis in the communities 
 
 
 
 
Table 3: Overall age-specific prevalence of Onchocerciasis in the sampled communities  
Age Range(years) Number Sampled Number infected % infected 
5 – 9 79 0 0 
10 – 19 62 0 0 
20 – 29 37 0 0 
30 – 39 37 0 0 
40 – 49 49 0 0 
50 – 59 77 0 0 
≥      60 206 3 1.46 
Total 547 3 0.55 
 
Communities 
Sampled 
Number 
Examined 
Number (%) 
Infected 
Male Female 
No (%) 
Examined  
No (%) 
Infected 
No (%) 
Examined 
No (%) 
Infected 
       
Umuobiala 63 – 
 
19 – 
 
44 – 
Amiyi-Obilohia 62 3(4.84) 16 1(6.25) 46 2(4.35) 
Obiagu-Uturu 36 – 15 – 21 – 
Amiyiuhu 98 – 37 – 61 – 
Mbala-Isuochi 104 – 43 – 61 – 
Amuda-Isuochi 42 – 16 – 26 – 
Amakpoke 70 – 34 – 36 – 
Lokpanta 72 – 21 – 51 – 
       
Total  sampled 547 3(0.55) 201 1(0.50) 346 2(0.58%) 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.3, No.12, 2013 
 
44 
Table 4: Community Microfilarial Load of Positive Individuals in the Sampled Communities 
Community  
Number of 
people sampled 
Total Num. of mf 
counted 
Total weight of 
skin 
CMFL 
(mf/mg) 
Umuobiala 63 0 87.50 0 
Amiyi Obilohia 62 55 196.26 0.28 
Obiagu-Uturu 36 0 125.00 0 
Amiyiuhu 98 0 207.50 0 
Mbala-Isuochi 104 0 253.00 0 
Amuda-Isuochi 42 0 269.5 0 
Amakpoke 70 0 218.00 0 
Lokpanta 72 0 182.50 0 
Total 547           55 1,539.26 0.28 
 
 
Table 5: Prevalence of Onchocercal symptoms among community members 
 
 
 
 
Applying the test statistic, χ2cal = 50.56, where χ2tab = 49.8 
 
4.0. Discussion 
After 14 years or more of annual mass drug administration with ivermectin, it was observed that there was 
remarkable reduction in the prevalence and intensity of onchocerciasis in the sampled communities. The study 
revealed a CMFL of 0.28mf/mg. This result agrees with the findings of Chijioke et al (1998) that after 3 annual 
ivermectin dosing rounds at Achi in Enugu state, CMFL was reduced from 2.56mf/mg to 0.43mf/mg. Alley et al 
(1994) also observed that a 93% reduction in microfilarial load was maintained one year after 5 successive 
annual ivermectin treatments. This result could be attributed to the mass treatment of endemic communities with 
ivermectin which had gone through 14 cycles of treatment and even more in some areas like Mbala-Isuochi, 
before the commencement of this study. This confirms the findings of some researchers that ivermectin has a 
prolong effect on skin microfilariae (Boatin et al., 1998; Dozie, 2002). It was not surprising that most 
Community 
No. 
examined  
No. of 
infected 
Itching 
Nodules 
impaired  
vision 
Leopard  
Skin 
 
Elephant skin 
Umuobiala 63 12(19.0) 2(3.2) 4(6.3) 3(4.8) 3(4.8) 0(0) 
Amiyi Obilohia 62 26(41.9) 6(9.7) 9(14.5) 9(14.5) 2(3.2) 0(0)    
Obiagu-Uturu 36 4(11.1) 0(0) 0(0) 2(5.6) 1(2.8) 0(0)  
Amiyiuhu 98 21(21.4) 4(4.1) 8(8.2) 6(6.1) 2(2.0) 1(1.0)  
Mbala-Isuochi 104 28(26.9) 5(4.8) 10(9.6) 8(7.7) 3(4.8) 0(0)  
Amuda-Isuochi 42 09(21.4) 2(4.8) 2(4.8) 4(9.5) 1(2.4) 0(0)  
Amakpoke 70 31(44.3) 3(4.3) 14(20.0) 14(20) 0(0) 0(0)  
Lokpanta 72 12(16.7) 2(2.8) 3(4.2) 3(4.2) 4(5.6) 0(0)  
          
Total 547 142(26.0 24(4.4) 50(9.1) 49(9.0) 18(3.3) 1(0.2)   
Number (%) of onchocercal symptoms 
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communities sampled recorded zero microfilariae, as the study in Senegal and Mali claimed that elimination can 
be achieved in most foci after 13 to 17 years of annual treatment (APOC/WHO, 2010). Onchocerciasis is 
considered an important public health problem when prevalence of microfilariae in the skin exceeds 40% of the 
total population of a community, or when the community microfilarial load (CMFL: a measure of the intensity of 
the infection in the community) exceeds 5mf/s (Diawara et al., 2009). A CMFL of 0.28mf/mg is a good move 
towards accomplishing APOC objective of eliminating onchocerciasis. 
The overall sex-related incidence of infection showed a similar pattern in males and females. The result showed 
that 0.50% of the males and 0.58% of the female are infected. This agrees with the findings of some authors like 
Edungbola (1991), Nwoke et al (1994) and Dozie et al (2006), that sex-differential with respect to infection may 
be the same in the rainforest zone irrespective of the degree of endemicity. The overall age-specific prevalence 
of onchocerciasis in the studied areas also showed that infection occurred only in ages 60 years and above. The 
absence of microfilariae in children 5 to 12 years of age is a confirmation that transmission can totally be 
interrupted in the studied areas as the incidence of infection in the 5 year old who were receiving Mectizan for 
the first time was zero. This finding is similar with the finding of Boatin et al (1998) that transmission was 
totally interrupted in the hypo-endemic Rio Geba Basin, as the prevalence was reduced by almost 100% and the 
incidence of infection in the 5 year old who were receiving Mectizan for the first time was zero.  
There have been several reports documenting improvement of some onchocercal symptoms after ivermectin 
treatment on onchocerciasis (Cousens et al., 1997; Chippaux et al., 1999). The most common onchocercal 
symptoms identified in this study were nodules (9.1%), impaired vision (9.0%), and itching (4.4%). The nodule 
rate of 9.1% shows a decrease from the >20% nodule rate specified for definite CDTI areas (Gemade et al., 
1998; Noma et al., 2002). This is an indication that annual treatment with ivermectin is effective. The claim by a 
respondent that his nodules disappeared after several annual ivermectin treatments provides credence to the 
findings of some researchers that onchocercal nodules were gradually disappearing with repeated doses of 
ivermectin (Ukaga et al., 2001; Emukah et al., 2004). The presence of onchocercal nodules and the absence of 
microfilariae in the skin of most individuals examined is indicative that ivermectin may have caused the 
calcification of the nodules, as well as some attrition in adult worm numbers and the viability of the survivors 
after multiply doses of ivermectin (Schulz-Key, 1990; Duck et al., 1990), thus giving credence to the 
susceptibility of the disease to repeated ivermectin treatment. The chi-square analysis on prevalence of the 
symptoms among the community members shows that prevalence is not the same among the different 
communities (P< 0.05). The major reason for this could be attributed to different rates of compliance among the 
community members. 
The impaired vision of 9.0% observed in this study was determined by inability to count fingers correctly at 
distance of six meters (Emukah et al., 2004). This is however a crude measure of visual acuity that can be easily 
explained, rapidly carried out, and reproducibly performed on illiterate population (Onabolu, 1989; Emukah et 
al., 2004s). The recommended criterion of the World Health Organization for functional blindness is the inability 
to count fingers at a distance of three meters; since twice that distance was used in this study, visual impairment 
was presented rather than functional blindness (WHO, 1995).  A weakness to this method of study is that ocular 
examination to classify or diagnose the clinical cause for the visual impairment was not carried out. This is an 
assumption which was not ascertained since the other blinding conditions like glaucoma, cataract etc, could be 
the cause. In conclusion, the present study revealed the absence of microfilarial in children 5 to 12 years of age 
and a reduction in the community microfilarial load to a less critical level (0.28mf/mg), after 14 years of annual 
ivermectin treatment. This is a good move towards accomplishing APOC objectives of eliminating 
onchocerciasis as disease of public health. It is suggested therefore, that the current control efforts   with annual 
dose of ivermectin be sustained.   
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